Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Verrienti

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Molecular and Cellular Endocrinology|June 6, 2017
Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancerMarilena Celano, Catia Mio, Marialuisa Sponziello, et al.
Frontiers in Oncology|September 12, 2022
Precision oncology for <i>RET</i>-related tumorsAntonella Verrienti, Giorgio Grani, Marialuisa Sponziello, et al.
Clinical Immunology (Orlando, Fla.)|May 17, 2005
IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetesClaudio Tiberti, Antonella Verrienti, Benedetta Fiore, et al.
Endocrine|December 6, 2022
Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cellsValentina Maggisano, Francesca Capriglione, Antonella Verrienti, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2009
GAD and IA-2 autoantibody detection in type 1 diabetic patient salivaClaudio Tiberti, Blegina Shashaj, Antonella Verrienti, et al.
Biochemical and Biophysical Research Communications|December 4, 2018
A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large familyMarianna Maranghi, Gessica Truglio, Antonio Gallo, et al.
Endocrine|March 10, 2019
BRAF<sup>V600E</sup>-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical responseRosa Falcone, Federica Conte, Giulia Fiscon, et al.
Scientific Reports|July 20, 2021
The role of FOSL1 in stem-like cell reprogramming processesValeria Pecce, Antonella Verrienti, Giulia Fiscon, et al.
Thyroid : Official Journal of the American Thyroid Association|December 24, 2011
Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cellsMaria D'Agostino, Pasquale Voce, Marilena Celano, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinomaLeonardo D'Aloiso, Francesca Carlomagno, Michele Bisceglia, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Molecular and Cellular Endocrinology|June 6, 2017
Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancerMarilena Celano, Catia Mio, Marialuisa Sponziello, et al.
Frontiers in Oncology|September 12, 2022
Precision oncology for <i>RET</i>-related tumorsAntonella Verrienti, Giorgio Grani, Marialuisa Sponziello, et al.
Clinical Immunology (Orlando, Fla.)|May 17, 2005
IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetesClaudio Tiberti, Antonella Verrienti, Benedetta Fiore, et al.
Endocrine|December 6, 2022
Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cellsValentina Maggisano, Francesca Capriglione, Antonella Verrienti, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2009
GAD and IA-2 autoantibody detection in type 1 diabetic patient salivaClaudio Tiberti, Blegina Shashaj, Antonella Verrienti, et al.
Biochemical and Biophysical Research Communications|December 4, 2018
A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large familyMarianna Maranghi, Gessica Truglio, Antonio Gallo, et al.
Endocrine|March 10, 2019
BRAF<sup>V600E</sup>-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical responseRosa Falcone, Federica Conte, Giulia Fiscon, et al.
Scientific Reports|July 20, 2021
The role of FOSL1 in stem-like cell reprogramming processesValeria Pecce, Antonella Verrienti, Giulia Fiscon, et al.
Thyroid : Official Journal of the American Thyroid Association|December 24, 2011
Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cellsMaria D'Agostino, Pasquale Voce, Marilena Celano, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinomaLeonardo D'Aloiso, Francesca Carlomagno, Michele Bisceglia, et al.
Pageof 6